Dr. Martens Plc (3U2) Stock Price & Analysis
3U2 Stock Chart & Stats
- Day’s Range
- EUR 0.76 - EUR 0.84
- 52-Week Range
- EUR 0.66 - EUR 1.07
- Previous Close
- EUR 0.75
- Volume
- 0
- Average Volume (3M)
- 412
- Market Cap
- EUR 752.59M
- Enterprise Value
- EUR 819.77M
- Total Cash (Recent Filing)
- EUR 180.30M
- Total Debt (Recent Filing)
- EUR 393.50M
- Price to Earnings (P/E)
- 26.3
- Beta
- 0.95
- Next Earnings
- Nov 19, 2026 (Est.)
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.84%
Bulls Say, Bears Say
Bulls Say
Cash Generation
Solid free cash flow and strong conversion relative to net income provide internal funding for operations, investment and shareholder returns. This cash-generation capacity can support the brand through weaker demand, although the pack notes that annual cash flow has been volatile.
Improving Leverage
The sustained reduction in debt-to-equity and decline in total debt improve financial resilience compared with prior years. Lower leverage can reduce balance-sheet pressure and preserve more flexibility for investment, despite the company still carrying meaningful debt relative to equity.
Operating Profit Rebound
The operating-margin rebound indicates that profitability can recover even while sales remain under pressure. If maintained, stronger operating earnings would improve cash generation and provide greater capacity to invest in product launches, channels and the global Dr. Martens brand.
Bears Say
Persistent Revenue Decline
Repeated annual revenue contraction signals weakening demand or reduced commercial momentum rather than a single-period fluctuation. Continued sales declines can limit operating leverage, reduce investment capacity and make it harder for the brand to regain its previous earnings scale.
Compressed Net Margins
Net profitability remains substantially below earlier levels despite the recovery from 2025. Persistently thinner margins leave less protection against further sales weakness and reduce the earnings benefit from each unit sold, making durable profit recovery dependent on sustained improvement.
Elevated Leverage And Lower Returns
Although leverage is improving, debt still exceeds equity and the company is not operating with a conservative capital structure. Combined with much lower return on equity than in 2022–2023, this constrains financial flexibility and indicates weaker capital productivity.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
What is Dr. Martens Plc’s market cap?
When is Dr. Martens Plc’s upcoming earnings report date?
How were Dr. Martens Plc’s earnings last quarter?
Is Dr. Martens Plc overvalued?
Does Dr. Martens Plc pay dividends?
What is Dr. Martens Plc’s EPS estimate?
How many shares outstanding does Dr. Martens Plc have?
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dr. Martens Plc?
What is the TipRanks Smart Score and how is it calculated?
Dr. Martens Plc Stock Smart Score
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
- Sector
- Consumercyclical
- Industry
- Apparel - Footwear & Accessories
- CEO
- Ije Nwokorie
- Employees
- 2,377
- Website
- www.drmartensplc.com
- Address
- 28 Jamestown Road, London, GL, NW1 7BY, GB
Dr. Martens Plc (3U2) Earnings & Revenues
3U2 Earnings Call
Earnings Call SentimentNeutral
The earnings call presented a mix of positive and negative aspects. There was notable improvement in revenue quality, operating profit, and debt reduction. Growth was observed in the Americas and APAC regions, along with an increase in full-price sales. However, challenges in the EMEA market, particularly in direct-to-consumer revenue, and ongoing issues with boots and sandals, along with tariff headwinds, were highlighted as areas of concern.
View all DE:3U2 earnings summaries3U2 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |
